CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society. The paper discusses results from CytRx's completed Phase 1b/2 clinical trial where 25 patients were enrolled, including 17 patients with advanced soft tissue sarcoma .